Elle traite des conditions comme la maladie de décompression, les infections et les brûlures.
Maladie de décompressionInfections
#2
Comment se déroule une séance d'oxygénation ?
Une séance se déroule dans une chambre pressurisée où le patient respire de l'oxygène pur.
Chambre hyperbareThérapie
#3
Quelle est la durée d'une séance ?
Une séance dure généralement entre 60 et 120 minutes, selon la condition traitée.
Durée de traitementThérapie
#4
Y a-t-il des effets secondaires ?
Les effets secondaires peuvent inclure des douleurs aux oreilles, des nausées ou des troubles visuels.
Effets secondairesNausées
#5
Qui peut administrer ce traitement ?
Le traitement doit être administré par des professionnels de santé formés en médecine hyperbare.
Médecine hyperbareProfessionnels de santé
Complications
5
#1
Quelles complications peuvent survenir ?
Les complications incluent des lésions pulmonaires, des convulsions et des infections.
ComplicationsLésions pulmonaires
#2
Comment gérer une embolie gazeuse ?
Une embolie gazeuse nécessite une intervention rapide, souvent avec une oxygénation hyperbare.
Embolie gazeuseIntervention médicale
#3
Quels risques liés à l'oxygénation hyperbare ?
Les risques incluent des barotraumatismes, des troubles de la vision et des réactions allergiques.
BarotraumatismesRéactions allergiques
#4
Comment prévenir les infections en chambre ?
Pour prévenir les infections, maintenez une bonne hygiène et suivez les protocoles de désinfection.
InfectionsHygiène
#5
Quels signes d'une complication grave ?
Des signes comme des douleurs thoraciques intenses ou des troubles neurologiques nécessitent une attention immédiate.
Complications gravesTroubles neurologiques
Facteurs de risque
5
#1
Quels sont les facteurs de risque de décompression ?
Les facteurs incluent la profondeur de plongée, la durée et l'absence de pauses de sécurité.
Facteurs de risquePlongée
#2
Qui est à risque d'intoxication à l'oxygène ?
Les plongeurs et les patients recevant une oxygénation hyperbare à haute pression sont à risque.
Intoxication à l'oxygènePlongeurs
#3
Quels antécédents augmentent les risques ?
Des antécédents de troubles respiratoires ou neurologiques peuvent augmenter les risques.
Antécédents médicauxTroubles respiratoires
#4
Comment l'âge influence-t-il les risques ?
Les personnes âgées peuvent avoir un risque accru de complications en raison de la fragilité des tissus.
ÂgeComplications
#5
Quels médicaments augmentent les risques ?
Certains médicaments, comme les diurétiques, peuvent augmenter le risque de déshydratation et de complications.
MédicamentsDéshydratation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Oxygénation hyperbare : Questions médicales les plus fréquentes",
"headline": "Oxygénation hyperbare : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Oxygénation hyperbare : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-26",
"dateModified": "2025-04-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Oxygénation hyperbare"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Oxygénothérapie",
"url": "https://questionsmedicales.fr/mesh/D010102",
"about": {
"@type": "MedicalCondition",
"name": "Oxygénothérapie",
"code": {
"@type": "MedicalCode",
"code": "D010102",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.880.690"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Oxygénation hyperbare",
"alternateName": "Hyperbaric Oxygenation",
"code": {
"@type": "MedicalCode",
"code": "D006931",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Richard E Moon",
"url": "https://questionsmedicales.fr/author/Richard%20E%20Moon",
"affiliation": {
"@type": "Organization",
"name": "Departments of Anesthesiology and Medicine, Center for Hyperbaric Medicine and Environmental Physiology, Duke University, North Carolina U.S."
}
},
{
"@type": "Person",
"name": "John P Kirby",
"url": "https://questionsmedicales.fr/author/John%20P%20Kirby",
"affiliation": {
"@type": "Organization",
"name": "John P. Kirby MD, FACS, is the Director of Wound Healing Programs, Associate Professor of Surgery, Section of Acute and Critical Care Surgery, at Washington University School of Medicine, Barnes-Jewish Hospital, in St. Louis, Missouri."
}
},
{
"@type": "Person",
"name": "Stephen R Thom",
"url": "https://questionsmedicales.fr/author/Stephen%20R%20Thom",
"affiliation": {
"@type": "Organization",
"name": "Emergency Medicine, University of Maryland, Baltimore, MD, USA."
}
},
{
"@type": "Person",
"name": "Michael H Bennett",
"url": "https://questionsmedicales.fr/author/Michael%20H%20Bennett",
"affiliation": {
"@type": "Organization",
"name": "Department of Diving and Hyperbaric Medicine, Prince of Wales Hospital and University of New South Wales, Sydney, New South Wales, Australia."
}
},
{
"@type": "Person",
"name": "Simon J Mitchell",
"url": "https://questionsmedicales.fr/author/Simon%20J%20Mitchell",
"affiliation": {
"@type": "Organization",
"name": "Department of Anaesthesiology, University of Auckland Faculty of Medicine, Auckland, New Zealand."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line.",
"datePublished": "2022-12-21",
"url": "https://questionsmedicales.fr/article/36613537",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24010097"
}
},
{
"@type": "ScholarlyArticle",
"name": "Promotion of tumor progression induced by continuous low-dose administration of antineoplastic agent gemcitabine or gemcitabine combined with cisplatin.",
"datePublished": "2022-07-21",
"url": "https://questionsmedicales.fr/article/35870618",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.lfs.2022.120826"
}
},
{
"@type": "ScholarlyArticle",
"name": "Drug independence and the curability of cancer by combination chemotherapy.",
"datePublished": "2022-07-14",
"url": "https://questionsmedicales.fr/article/35842290",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.trecan.2022.06.009"
}
},
{
"@type": "ScholarlyArticle",
"name": "Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.",
"datePublished": "2024-05-02",
"url": "https://questionsmedicales.fr/article/38695605",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD013595.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study.",
"datePublished": "2023-03-13",
"url": "https://questionsmedicales.fr/article/36914193",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjopen-2022-069401"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Thérapeutique",
"item": "https://questionsmedicales.fr/mesh/D013812"
},
{
"@type": "ListItem",
"position": 3,
"name": "Thérapie respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012138"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxygénothérapie",
"item": "https://questionsmedicales.fr/mesh/D010102"
},
{
"@type": "ListItem",
"position": 5,
"name": "Oxygénation hyperbare",
"item": "https://questionsmedicales.fr/mesh/D006931"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Oxygénation hyperbare - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Oxygénation hyperbare",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Oxygénation hyperbare",
"description": "Comment diagnostiquer une décompression ?\nQuels tests pour l'oxygénation hyperbare ?\nQuels symptômes indiquent un traitement ?\nComment évaluer l'efficacité du traitement ?\nQuels critères pour l'admission en chambre hyperbare ?",
"url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Antineoplastic+Combined+Chemotherapy+Protocols#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Oxygénation hyperbare",
"description": "Quels sont les symptômes de l'oxygénation hyperbare ?\nComment se manifeste l'intoxication à l'oxygène ?\nQuels signes d'une embolie gazeuse ?\nQuels symptômes après une séance d'oxygénation ?\nComment reconnaître une réaction allergique ?",
"url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Antineoplastic+Combined+Chemotherapy+Protocols#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Oxygénation hyperbare",
"description": "Comment prévenir la maladie de décompression ?\nQuelles précautions avant une séance ?\nComment éviter l'intoxication à l'oxygène ?\nQuelles sont les recommandations post-traitement ?\nComment se préparer psychologiquement ?",
"url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Antineoplastic+Combined+Chemotherapy+Protocols#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Oxygénation hyperbare",
"description": "Quelles conditions traitent l'oxygénation hyperbare ?\nComment se déroule une séance d'oxygénation ?\nQuelle est la durée d'une séance ?\nY a-t-il des effets secondaires ?\nQui peut administrer ce traitement ?",
"url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Antineoplastic+Combined+Chemotherapy+Protocols#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Oxygénation hyperbare",
"description": "Quelles complications peuvent survenir ?\nComment gérer une embolie gazeuse ?\nQuels risques liés à l'oxygénation hyperbare ?\nComment prévenir les infections en chambre ?\nQuels signes d'une complication grave ?",
"url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Antineoplastic+Combined+Chemotherapy+Protocols#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Oxygénation hyperbare",
"description": "Quels sont les facteurs de risque de décompression ?\nQui est à risque d'intoxication à l'oxygène ?\nQuels antécédents augmentent les risques ?\nComment l'âge influence-t-il les risques ?\nQuels médicaments augmentent les risques ?",
"url": "https://questionsmedicales.fr/mesh/D006931?mesh_terms=Antineoplastic+Combined+Chemotherapy+Protocols#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une décompression ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic de décompression se fait par l'évaluation des symptômes et des antécédents d'immersion."
}
},
{
"@type": "Question",
"name": "Quels tests pour l'oxygénation hyperbare ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie et des évaluations cliniques sont utilisés pour déterminer l'indication."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un traitement ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des douleurs articulaires, des troubles neurologiques ou des brûlures peuvent indiquer un traitement."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du traitement ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par l'amélioration des symptômes et des tests de suivi après traitement."
}
},
{
"@type": "Question",
"name": "Quels critères pour l'admission en chambre hyperbare ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent des conditions médicales spécifiques et l'absence de contre-indications."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'oxygénation hyperbare ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des douleurs, des vertiges, et des troubles de la vision."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'intoxication à l'oxygène ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'intoxication à l'oxygène se manifeste par des convulsions, des nausées et des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Quels signes d'une embolie gazeuse ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des douleurs thoraciques, des difficultés respiratoires et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes après une séance d'oxygénation ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Après une séance, des sensations de fatigue ou de légers maux de tête peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une réaction allergique peut se manifester par des éruptions cutanées, des démangeaisons ou un gonflement."
}
},
{
"@type": "Question",
"name": "Comment prévenir la maladie de décompression ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut une ascension lente après la plongée et des pauses de sécurité."
}
},
{
"@type": "Question",
"name": "Quelles précautions avant une séance ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez de fumer, de consommer de l'alcool et informez le médecin de vos antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Comment éviter l'intoxication à l'oxygène ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pour éviter l'intoxication, respectez les protocoles de traitement et les durées recommandées."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations post-traitement ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Après traitement, reposez-vous et évitez les activités physiques intenses pendant 24 heures."
}
},
{
"@type": "Question",
"name": "Comment se préparer psychologiquement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Préparez-vous en vous informant sur le traitement et en discutant avec des professionnels."
}
},
{
"@type": "Question",
"name": "Quelles conditions traitent l'oxygénation hyperbare ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle traite des conditions comme la maladie de décompression, les infections et les brûlures."
}
},
{
"@type": "Question",
"name": "Comment se déroule une séance d'oxygénation ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une séance se déroule dans une chambre pressurisée où le patient respire de l'oxygène pur."
}
},
{
"@type": "Question",
"name": "Quelle est la durée d'une séance ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une séance dure généralement entre 60 et 120 minutes, selon la condition traitée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des douleurs aux oreilles, des nausées ou des troubles visuels."
}
},
{
"@type": "Question",
"name": "Qui peut administrer ce traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement doit être administré par des professionnels de santé formés en médecine hyperbare."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des lésions pulmonaires, des convulsions et des infections."
}
},
{
"@type": "Question",
"name": "Comment gérer une embolie gazeuse ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une embolie gazeuse nécessite une intervention rapide, souvent avec une oxygénation hyperbare."
}
},
{
"@type": "Question",
"name": "Quels risques liés à l'oxygénation hyperbare ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des barotraumatismes, des troubles de la vision et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections en chambre ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pour prévenir les infections, maintenez une bonne hygiène et suivez les protocoles de désinfection."
}
},
{
"@type": "Question",
"name": "Quels signes d'une complication grave ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques intenses ou des troubles neurologiques nécessitent une attention immédiate."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de décompression ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent la profondeur de plongée, la durée et l'absence de pauses de sécurité."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'intoxication à l'oxygène ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les plongeurs et les patients recevant une oxygénation hyperbare à haute pression sont à risque."
}
},
{
"@type": "Question",
"name": "Quels antécédents augmentent les risques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de troubles respiratoires ou neurologiques peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il les risques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent avoir un risque accru de complications en raison de la fragilité des tissus."
}
},
{
"@type": "Question",
"name": "Quels médicaments augmentent les risques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments, comme les diurétiques, peuvent augmenter le risque de déshydratation et de complications."
}
}
]
}
]
}
John P. Kirby MD, FACS, is the Director of Wound Healing Programs, Associate Professor of Surgery, Section of Acute and Critical Care Surgery, at Washington University School of Medicine, Barnes-Jewish Hospital, in St. Louis, Missouri.
Department of Clinical Microbiology, Rigshospitalet, Copenhagen University Hospital and Department of Immunology and Microbiology (ISIM), University of Copenhagen, Denmark.
Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet and Department of Immunology and Microbiology (ISIM), University of Copenhagen, Denmark.
The combination of Carboplatin with Paclitaxel is the mainstay treatment for high-grade serous carcinoma; however, many patients with advanced disease undergo relapse due to chemoresistance. Drug repu...
This study observes a previously neglected pharmacological phenomenon and investigates its mechanism of that the continuous low-dose administration of some antineoplastic agents in certain dose ranges...
There are indications that certain antineoplastic agents at low dosages may exhibit abnormal pharmacological actions, such as promoting tumor growth. However, the phenomenon still needs to be further ...
Gemcitabine (GEM) and cisplatin (CDDP) were employed as representative antineoplastic agents to observe effects of continuous low-dose chemotherapy with GEM or GEM combined with CDDP (GEM+CDDP) on tum...
The results showed that tumor formation and growth were both significantly promoted by GEM or GEM+CDDP at as low as half of the metronomic dosages, which were accompanied by enhancements of angiogenes...
These findings indicate that, the continuous low-dose administration of GEM and GEM+CDDP can promote tumorigenesis and tumor progression in vivo by inhibiting apoptosis, mobilizing BMDCs, and promotin...
Combination chemotherapy can cure certain leukemias and lymphomas, but most solid cancers are only curable at early stages. We review quantitative principles that explain the benefits of combining ind...
Multiple myeloma (MM) is a haematological malignancy that is characterised by proliferation of malignant plasma cells in the bone marrow. For adults ineligible to receive high-dose chemotherapy and au...
To determine the benefits and harms of daratumumab in addition to antineoplastic therapy compared to antineoplastic therapy only for adults with newly diagnosed MM who are ineligible for transplant....
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, EU Clinical Trials Register, ClinicalTrials.gov, WHO ICTRP, and conference proceedings from 2010 to September...
We included randomised controlled trials that compared treatment with daratumumab added to antineoplastic therapy versus the same antineoplastic therapy alone in adult participants with a confirmed di...
Two review authors independently screened the results of the search strategies for eligibility. We documented the process of study selection in a flowchart as recommended by the PRISMA statement. We e...
We included four open-label, two-armed randomised controlled trials (34 publications) involving a total of 1783 participants. The ALCYONE, MAIA, and OCTANS trials were multicentre trials conducted wor...
Overall analysis of four studies showed a potential benefit for daratumumab in terms of overall survival and progression-free survival and a slight potential benefit in quality of life. Participants t...
The NICHE trial showed remarkable results of neoadjuvant immunotherapy in colorectal cancer patients with mismatch repair (MMR) deficiency (dMMR). However, rectal cancer patients with dMMR accounted f...
First, recruited patients will receive neoadjuvant arterial embolisation chemotherapy (NAEC) with oxaliplatin 85 mg/m...
The Human Research Ethics Committee of the Fourth Affiliated Hospital of Zhejiang University School of Medicine approved this study protocol. The results will be published in peer-reviewed journals an...
NCT05420584....
Although 80% of patients with metastatic colorectal cancer (CRC) experience liver metastases, only 10-25% undergo resection at the time of diagnosis. Even in initially unresectable conditions, if appr...
This is a single-center, randomized, open-label phase II trial (NCT05103020). Patients with untreated CRC, who have liver-only metastases and for whom liver resection is potentially possible but deeme...
This is the first randomized controlled trial to investigate the efficacy of HAI oxaliplatin in combination with sys-CT plus targeted therapy as first-line treatment from the initial diagnosis in pati...
ClinicalTrials.gov, (NCT05103020). Trial registration date: November 2, 2021....
Short-course radiotherapy (SCRT) with systemic therapy has the potential to further improve the long-term efficacy in patients with locally advanced rectal cancer (LARC). To maximise the benefits of n...
Fifty treatment-naïve patients with operable LARC (T3-4 and/or N+) will be recruited. Patients will be synchronously treated with capecitabine plus oxaliplatin (CAPOX) chemotherapy, tislelizumab and p...
The study protocol was approved by the Ethics Committee of Xiehe Affiliated Hospital of Fujian Medical University (XAHFMU) (No. 2021YF025-01). Results from our study will be disseminated in internatio...
NCT05176964....
Venetoclax is frequently used as salvage treatment in pediatric, adolescent, and young adult (AYA) patients with advanced hematologic malignancies. However, more data are needed from real-world studie...
We retrospectively reviewed the medical records of all patients diagnosed with hematologic malignancies less than 30 years of age treated with venetoclax outside of clinical trials at the University o...
We identified 13 patients (acute myeloid leukemia, n = 8; B-acute lymphoblastic leukemia, n = 3; myelodysplastic syndrome, n = 2) aged 4 months to 27 years. A median of 3 prior lines of therapy weregi...
Venetoclax in combination with hypomethylating agents or cytotoxic chemotherapy was effective in a subset of pediatric/AYA patients with advanced hematologic malignancies, but multiple severe infectio...
The limitations associated with cancer monotherapy including dose dependent toxicity and drug resistance can be addressed by combination chemotherapy. The combination of antineoplastic agents improves...
Neoadjuvant chemotherapy (nCT) or neoadjuvant chemoradiotherapy followed by surgery has been recommended as standard treatment in patients with locally advanced esophageal cancer (LAEC). But the risk ...
In this retrospective study, patients with resectable esophageal cancer who received surgery after nICT (n=26, 40%) or nCT alone (n=39, 60%) were included. The patients were classified as nICT or nCT ...
Three (11.5%) of the 26 patients achieved pathological complete remission (pCR) in the nICT group, and four (10.3%) of the 39 patients achieved pCR in the nCT group, respectively (P=1.000). Six (23.1%...
Neoadjuvant PD-1 blockade combined with chemotherapy was not superior to chemotherapy alone for patients with resectable locally advanced esophageal carcinoma. However, more studies with long-term fol...